Search research articles
Contact Us
Filters
Showing results (221-230 of 248) with videos related to
Page
of 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
Simon J Crabb, Gareth Griffiths, Ellice Marwood, et al.
Trials
|
August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
Tom Wilkinson, Rupert Dixon, Clive Page, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 9, 2024
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people
Tracey H Sach, Mary Onoja, Holly Clarke, et al.
BMJ Open
|
February 7, 2021
Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers
Ingrid Muller, Beth Stuart, Tracey Sach, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
BMJ Open
|
April 9, 2025
Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal (UNIVERSAL) study: a prospective observational cohort study protocol
Tommaso Morelli, Martha Purcell, Pedro Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
Health Technology Assessment (Winchester, England)
|
March 29, 2024
Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
Tony Kendrick, Christopher Dowrick, Glyn Lewis, et al.
Page
of 25
Search research articles
Search
Showing results (221-230 of 248) with videos related to
Sort By:
Page
of 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
Simon J Crabb, Gareth Griffiths, Ellice Marwood, et al.
Trials
|
August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
Tom Wilkinson, Rupert Dixon, Clive Page, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew J Davies, Sharon Barrans, Louise Stanton, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
January 9, 2024
Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people
Tracey H Sach, Mary Onoja, Holly Clarke, et al.
BMJ Open
|
February 7, 2021
Supporting self-care for eczema: protocol for two randomised controlled trials of ECO (Eczema Care Online) interventions for young people and parents/carers
Ingrid Muller, Beth Stuart, Tracey Sach, et al.
The Lancet. Oncology
|
April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas E Cummin, Sharon Barrans, et al.
BMJ Open
|
April 9, 2025
Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal (UNIVERSAL) study: a prospective observational cohort study protocol
Tommaso Morelli, Martha Purcell, Pedro Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2025
CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E Buermann, Louise Stanton, Matthew J J Rose-Zerilli, et al.
Health Technology Assessment (Winchester, England)
|
March 29, 2024
Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation
Tony Kendrick, Christopher Dowrick, Glyn Lewis, et al.
Page
of 25